Model for CD137 targeted prevention of GVHD. In the NHP model, presented by Gerdemann et al, a single-dose CD137-ADC selectively depletes CD137⁺ PD-1⁺–activated T-cells at the time of transplant, while sparing naïve, memory, and regulatory T-cell subsets to preserve immune reconstitution and prevent GVHD.